Juefeng Q. Wan

Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity.

Journal: Frontiers in immunology

Published: May 03, 2026

Integrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer.

Journal: Therapeutic advances in medical oncology

Published: April 29, 2026

Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial.

Journal: BMJ open

Published: April 16, 2026

Short-Course Radiotherapy Combined With CapeOx and PD-1 Inhibitor Following Local Excision in High-Risk Early Rectal Cancer: Study Protocol for a Prospective Phase II Trial (TORCH-LE).

Journal: Clinical Medicine Insights. Oncology

Published: April 10, 2026

Pathological lymph node response after immunotherapy-based total neoadjuvant therapy supports local excision for organ preservation in locally advanced rectal cancer: a propensity-score weighted analysis.

Journal: Clinical and translational radiation oncology

Published: December 01, 2025

Development and internal validation of a prognostic nomogram for lung metastasis in locally advanced rectal cancer incorporating molecular markers.

Journal: Translational cancer research

Published: October 21, 2025

Comparison of Thrombocytopenia and Splenomegaly in Locally Advanced Rectal Cancer Patients Receiving Total Neoadjuvant Therapy With and Without Immunotherapy.

Journal: Cancer medicine

Published: October 20, 2025

Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial.

Journal: Cancer communications (London, England)

Published: April 24, 2025

Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 18, 2025

SIRPα + CD209 + cell: a specialized antigen-presenting cell that contributes to anti-SIRPα/RT therapy in colorectal cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: December 18, 2024

Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity.

Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity.

Integrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer.

Integrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer.

Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial.

Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial.

Short-Course Radiotherapy Combined With CapeOx and PD-1 Inhibitor Following Local Excision in High-Risk Early Rectal Cancer: Study Protocol for a Prospective Phase II Trial (TORCH-LE).

Short-Course Radiotherapy Combined With CapeOx and PD-1 Inhibitor Following Local Excision in High-Risk Early Rectal Cancer: Study Protocol for a Prospective Phase II Trial (TORCH-LE).

Pathological lymph node response after immunotherapy-based total neoadjuvant therapy supports local excision for organ preservation in locally advanced rectal cancer: a propensity-score weighted analysis.

Pathological lymph node response after immunotherapy-based total neoadjuvant therapy supports local excision for organ preservation in locally advanced rectal cancer: a propensity-score weighted analysis.

Development and internal validation of a prognostic nomogram for lung metastasis in locally advanced rectal cancer incorporating molecular markers.

Development and internal validation of a prognostic nomogram for lung metastasis in locally advanced rectal cancer incorporating molecular markers.

Comparison of Thrombocytopenia and Splenomegaly in Locally Advanced Rectal Cancer Patients Receiving Total Neoadjuvant Therapy With and Without Immunotherapy.

Comparison of Thrombocytopenia and Splenomegaly in Locally Advanced Rectal Cancer Patients Receiving Total Neoadjuvant Therapy With and Without Immunotherapy.

Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial.

Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial.

Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study.

Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study.

SIRPα + CD209 + cell: a specialized antigen-presenting cell that contributes to anti-SIRPα/RT therapy in colorectal cancer.

SIRPα + CD209 + cell: a specialized antigen-presenting cell that contributes to anti-SIRPα/RT therapy in colorectal cancer.

Comprehensive dissection of rectal cancer organoids in responses to chemoradiation.

Comprehensive dissection of rectal cancer organoids in responses to chemoradiation.

Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis.

Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis.